Developer docs
API playgroundTry for free, no card

Search company profiles

Neuland Laboratories

Full company profile

uuid000a1ei

Namestring
Neuland Laboratories
Legal namestring
Neuland Laboratories Ltd.
Websiteurl
neulandlabs.com
Company typeenum
Public
Founded yearint
1984
Descriptiontext

Neuland Laboratories Limited is a Hyderabad-headquartered, publicly listed (NSE: NEULANDLAB) Active Pharmaceutical Ingredient (API) manufacturer and Contract Development and Manufacturing Organization (CDMO) founded in 1984. The company operates three US FDA-inspected manufacturing facilities in Telangana, India (Bonthapally, Pashamylaram, and Gaddapotharam) supported by an R&D Centre, and serves more than 500 pharmaceutical and biotech customers across 80+ countries. Neuland's offering spans three product lines: (1) generic APIs split into Prime (high-volume mature molecules) and Specialty (lower-volume, complex) categories, (2) end-to-end CDMO services covering custom development, process optimization, analytical testing, and regulatory CMC support from Pre-IND through commercial supply, and (3) custom peptide development and manufacturing via Solid-Phase Peptide Synthesis (SPPS) and Liquid-Phase Peptide Synthesis (LPPS) capabilities, including a new commercial peptide module targeting GLP-1 and innovator biotech demand.

The underlying technology platform is built on complex small-molecule and peptide chemistry, anchored by proprietary capabilities in SPPS and LPPS, Green Chemistry by Design (GCbD) process integration aligned with Quality by Design (QbD), and the NeuACTS sustainable supplier engagement program. Quality and regulatory infrastructure is the company's structural backbone: cGMP certifications from US FDA, EMA, EDQM, TGA, PMDA, CFDA, Health Canada, KFDA, ANVISA, Cofepris, and the German Health Authority, plus ISO 9001/14001/27001 and OHSAS 18001, enable global commercial supply. Neuland employs approximately 2,000 people and draws on India's deep life-sciences talent pipeline to maintain a stated 30-40% cost advantage versus Western CDMOs.

Commercially, Neuland runs a B2B enterprise field-sales model with regional offices in India, Japan, the US (Princeton, NJ), and Switzerland, complemented by participation in industry events such as BOS Basel and CPHI NorthAmerica. Pricing is quote-based and project-tied, with multi-year contracts typical for CDMO engagements; revenue streams are project-based rather than subscription or license-recurring. Recent financial performance demonstrates sharp inflection: FY26 total income reached Rs 20,531 million with EBITDA of Rs 6,034 million, while Q4FY26 revenue grew 136% YoY and the CDMO segment grew 366% YoY, accompanied by EBITDA margin expansion to 40.5%. Capacity additions (120.5 KL expansion at Unit I for Rs 143.4 crore; 6,370 L new peptide module with ~USD 30 million in firm commitments) and the April 2026 leadership transition to Saharsh Davuluri as CEO indicate an aggressive scaling posture targeting a top-five global API CDMO position within a decade.

Short descriptiontext

Neuland Laboratories is a Hyderabad-based publicly listed API manufacturer and CDMO serving 500+ pharma and biotech customers across 80+ countries from three US FDA-inspected facilities, offering generic APIs, custom CDMO services, and peptide manufacturing including SPPS/LPPS capabilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, contract development manufacturing, peptide manufacturing services, generic API manufacturing, pharmaceutical CDMO services
Industry5 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • Industrial Organic Chemicals2860
Product category
Pharmaceutical API Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Generic API Manufacturing
TypeOne Time License
Description

Development and manufacturing of non-exclusive Active Pharmaceutical Ingredients including Prime APIs (large volume, mature molecules) and Specialty APIs (lower volume, complex molecules with less competition) for quality-conscious customers globally

neulandlabs.com
2CDMO Services (Contract Development and Manufacturing)
TypeProfessional Services
Description

End-to-end continuum of customized NCE development services from lab to commercial supply, including process development, process optimization, analytical testing, and regulatory support. The CDMO segment showed 366% YoY growth in Q4FY26

neulandlabs.com
3Peptide Development and Manufacturing
TypeOne Time License
Description

Custom peptide synthesis services including process development and large-scale cGMP manufacturing for clinical trials and commercial production

neulandlabs.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing for API and peptide manufacturing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed - pricing varies based on molecule complexity, volume requirements, regulatory requirements, and project scope

neulandlabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neuland Laboratories develops, manufactures, and supplies Active Pharmaceutical Ingredients (APIs) for global pharmaceutical and biotech companies. Its offering includes generic APIs (Prime and Specialty), end-to-end Contract Development and Manufacturing Organization (CDMO) services spanning process development, analytical development, and commercial cGMP manufacturing for New Chemical Entities (NCEs), and custom peptide synthesis and large-scale peptide manufacturing (SPPS and LPPS).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Q4FY26 revenue grew 136% YoY with PAT growth of 666%
+2 more records
Product and service1 record
1Generic APIs
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1LIR Life Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-05
Description

LIR Life Sciences has commenced Project Phase 2 peptide design activities with Neuland Laboratories under their existing services agreement. The collaboration focuses on design and optimization of next-generation cell-penetrating peptides for LIR's transdermal delivery platform. The program involves systematic structure-activity relationship analysis to develop third-generation peptide candidates with improved performance and manufacturability potential.

morningstar.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading Indian API manufacturer with significant CDMO/custom synthesis operations serving global pharma customers. Most direct comparable given its API focus, India base, US FDA-inspected facilities, and growing CDMO/peptide exposure.

TypeDirect peer
Description

Indian API and CDMO company with strong small-molecule synthesis capabilities and growing peptide/biologics CDMO services. Direct peer in Indian API space with similar customer base of global pharma and biotech clients.

3Syngene International
TypeDirect peer
Description

India-headquartered contract research and manufacturing organization (CRAM) offering integrated drug discovery, development, and manufacturing services. Direct peer in Indian CDMO space with comparable global pharma customer base.

TypeDirect peer
Description

Indian pharma company with significant CDMO operations including radiopharmaceuticals, APIs, and contract manufacturing. Comparable in CDMO service offering and customer mix of global innovators.

TypeDirect peer
Description

Global CDMO offering integrated API and finished dosage form development and manufacturing services. Direct peer in CDMO space with comparable complex chemistry capabilities and customer base of innovator pharma companies.

TypeDirect peer
Description

Swiss-headquartered global leader in peptide and oligonucleotide CDMO services. Most direct peer in the peptide CDMO segment where Neuland is investing heavily, targeting similar biotech and GLP-1 customers.

TypeBroad incumbent
Description

World's largest CDMO offering small molecules, biologics, cell and gene therapy services. Broad incumbent in the CDMO space with overlapping API and peptide capabilities but serving as part of a much wider portfolio.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with significant API manufacturing operations serving global markets. Broader incumbent in Indian API space with wider generics portfolio and USFDA-inspected facilities.

TypeDirect peer
Description

Specialty CDMO focused on small-molecule API development and manufacturing from clinical to commercial scale. Direct peer in small-molecule CDMO with comparable complex chemistry capabilities and pharma/biotech customer base.

TypeBroad incumbent
Description

Major Indian pharmaceutical company with API manufacturing operations and growing CDMO services. Broader incumbent with overlapping API capabilities and similar regulatory compliance footprint across global markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuland Laboratories

Pharmaceutical API Manufacturingneulandlabs.com

Neuland Laboratories is a Hyderabad-based publicly listed API manufacturer and CDMO serving 500+ pharma and biotech customers across 80+ countries from three US FDA-inspected facilities, offering generic APIs, custom CDMO services, and peptide manufacturing including SPPS/LPPS capabilities.

What Neuland Laboratories does

Neuland Laboratories Limited is a Hyderabad-headquartered, publicly listed (NSE: NEULANDLAB) Active Pharmaceutical Ingredient (API) manufacturer and Contract Development and Manufacturing Organization (CDMO) founded in 1984. The company operates three US FDA-inspected manufacturing facilities in Telangana, India (Bonthapally, Pashamylaram, and Gaddapotharam) supported by an R&D Centre, and serves more than 500 pharmaceutical and biotech customers across 80+ countries. Neuland's offering spans three product lines: (1) generic APIs split into Prime (high-volume mature molecules) and Specialty (lower-volume, complex) categories, (2) end-to-end CDMO services covering custom development, process optimization, analytical testing, and regulatory CMC support from Pre-IND through commercial supply, and (3) custom peptide development and manufacturing via Solid-Phase Peptide Synthesis (SPPS) and Liquid-Phase Peptide Synthesis (LPPS) capabilities, including a new commercial peptide module targeting GLP-1 and innovator biotech demand.

The underlying technology platform is built on complex small-molecule and peptide chemistry, anchored by proprietary capabilities in SPPS and LPPS, Green Chemistry by Design (GCbD) process integration aligned with Quality by Design (QbD), and the NeuACTS sustainable supplier engagement program. Quality and regulatory infrastructure is the company's structural backbone: cGMP certifications from US FDA, EMA, EDQM, TGA, PMDA, CFDA, Health Canada, KFDA, ANVISA, Cofepris, and the German Health Authority, plus ISO 9001/14001/27001 and OHSAS 18001, enable global commercial supply. Neuland employs approximately 2,000 people and draws on India's deep life-sciences talent pipeline to maintain a stated 30-40% cost advantage versus Western CDMOs.

Commercially, Neuland runs a B2B enterprise field-sales model with regional offices in India, Japan, the US (Princeton, NJ), and Switzerland, complemented by participation in industry events such as BOS Basel and CPHI NorthAmerica. Pricing is quote-based and project-tied, with multi-year contracts typical for CDMO engagements; revenue streams are project-based rather than subscription or license-recurring. Recent financial performance demonstrates sharp inflection: FY26 total income reached Rs 20,531 million with EBITDA of Rs 6,034 million, while Q4FY26 revenue grew 136% YoY and the CDMO segment grew 366% YoY, accompanied by EBITDA margin expansion to 40.5%. Capacity additions (120.5 KL expansion at Unit I for Rs 143.4 crore; 6,370 L new peptide module with ~USD 30 million in firm commitments) and the April 2026 leadership transition to Saharsh Davuluri as CEO indicate an aggressive scaling posture targeting a top-five global API CDMO position within a decade.

Neuland Laboratories firmographics

Firmographics
Name
Neuland Laboratories
Legal name
Neuland Laboratories Ltd.
Website
https://neulandlabs.com
Company type
Public
Founded year
1984
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Neuland Laboratories is a Hyderabad-based publicly listed API manufacturer and CDMO serving 500+ pharma and biotech customers across 80+ countries from three US FDA-inspected facilities, offering generic APIs, custom CDMO services, and peptide manufacturing including SPPS/LPPS capabilities.
Ownership category
akta.pro rank

Neuland Laboratories industry classification

Industry
Product category
Pharmaceutical API Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Active pharmaceutical ingredients
  • Contract development manufacturing
  • Peptide manufacturing services
  • Generic API manufacturing
  • Pharmaceutical CDMO services

Where Neuland Laboratories is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices8 records

Markets served

Neuland Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Generic API Manufacturing: Development and manufacturing of non-exclusive Active Pharmaceutical Ingredients including Prime APIs (large volume, mature molecules) and Specialty APIs (lower volume, complex molecules with less competition) for quality-conscious customers globally
  2. CDMO Services (Contract Development and Manufacturing): End-to-end continuum of customized NCE development services from lab to commercial supply, including process development, process optimization, analytical testing, and regulatory support. The CDMO segment showed 366% YoY growth in Q4FY26
  3. Peptide Development and Manufacturing: Custom peptide synthesis services including process development and large-scale cGMP manufacturing for clinical trials and commercial production

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for API and peptide manufacturing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Neuland Laboratories product offering

Product offering

Core offering

Neuland Laboratories develops, manufactures, and supplies Active Pharmaceutical Ingredients (APIs) for global pharmaceutical and biotech companies. Its offering includes generic APIs (Prime and Specialty), end-to-end Contract Development and Manufacturing Organization (CDMO) services spanning process development, analytical development, and commercial cGMP manufacturing for New Chemical Entities (NCEs), and custom peptide synthesis and large-scale peptide manufacturing (SPPS and LPPS).

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic APIs

Quantifiable outcome

  • Q4FY26 revenue grew 136% YoY with PAT growth of 666%
  • +2 more outcomes

Companies that use Neuland Laboratories

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Neuland Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Neuland Laboratories partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LIR Life SciencescoreStrategic or Co-development Partner · 5 February 2026LIR Life Sciences has commenced Project Phase 2 peptide design activities with Neuland Laboratories under their existing services agreement. The collaboration focuses on design and optimization of next-generation cell-penetrating peptides for LIR's transdermal delivery platform. The program involves systematic structure-activity relationship analysis to develop third-generation peptide candidates with improved performance and manufacturability potential.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Neuland Laboratories competitors and assessment

Company assessment

Direct peers

  • Divi's Laboratories: Leading Indian API manufacturer with significant CDMO/custom synthesis operations serving global pharma customers. Most direct comparable given its API focus, India base, US FDA-inspected facilities, and growing CDMO/peptide exposure.
  • Laurus Labs: Indian API and CDMO company with strong small-molecule synthesis capabilities and growing peptide/biologics CDMO services. Direct peer in Indian API space with similar customer base of global pharma and biotech clients.
  • Syngene International: India-headquartered contract research and manufacturing organization (CRAM) offering integrated drug discovery, development, and manufacturing services. Direct peer in Indian CDMO space with comparable global pharma customer base.
  • Jubilant Pharmova: Indian pharma company with significant CDMO operations including radiopharmaceuticals, APIs, and contract manufacturing. Comparable in CDMO service offering and customer mix of global innovators.
  • Piramal Pharma Solutions: Global CDMO offering integrated API and finished dosage form development and manufacturing services. Direct peer in CDMO space with comparable complex chemistry capabilities and customer base of innovator pharma companies.
  • Bachem: Swiss-headquartered global leader in peptide and oligonucleotide CDMO services. Most direct peer in the peptide CDMO segment where Neuland is investing heavily, targeting similar biotech and GLP-1 customers.
  • Cambrex: Specialty CDMO focused on small-molecule API development and manufacturing from clinical to commercial scale. Direct peer in small-molecule CDMO with comparable complex chemistry capabilities and pharma/biotech customer base.

Broad incumbents

  • Lonza Group: World's largest CDMO offering small molecules, biologics, cell and gene therapy services. Broad incumbent in the CDMO space with overlapping API and peptide capabilities but serving as part of a much wider portfolio.
  • Aurobindo Pharma: Large Indian pharmaceutical company with significant API manufacturing operations serving global markets. Broader incumbent in Indian API space with wider generics portfolio and USFDA-inspected facilities.
  • Dr. Reddy's Laboratories: Major Indian pharmaceutical company with API manufacturing operations and growing CDMO services. Broader incumbent with overlapping API capabilities and similar regulatory compliance footprint across global markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Neuland Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuland Laboratories leadership team

Management profile

Number of profiles

Profiles6 records

Neuland Laboratories funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuland Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuland Laboratories

What does Neuland Laboratories do?

Neuland Laboratories develops, manufactures, and supplies Active Pharmaceutical Ingredients (APIs) for global pharmaceutical and biotech companies. Its offering includes generic APIs (Prime and Specialty), end-to-end Contract Development and Manufacturing Organization (CDMO) services spanning process development, analytical development, and commercial cGMP manufacturing for New Chemical Entities (NCEs), and custom peptide synthesis and large-scale peptide manufacturing (SPPS and LPPS).

Is Neuland Laboratories a public or private company?

Neuland Laboratories is a public company. It is classified as public and is currently operating.

When was Neuland Laboratories founded?

Neuland Laboratories was founded in 1984. It employs 1,001 to 5,000 people.

Where is Neuland Laboratories based?

Neuland Laboratories is headquartered in Hyderabad, India, in the Asia region.

How does Neuland Laboratories make money?

Three revenue lines are on record. Generic API Manufacturing is the primary driver. The others are CDMO Services (Contract Development and Manufacturing) and peptide Development and Manufacturing.

Who are Neuland Laboratories's main competitors?

Direct peers on record are Divi's Laboratories, Laurus Labs, Syngene International, Jubilant Pharmova, Piramal Pharma Solutions, Bachem and Cambrex. Broad incumbents are Lonza Group, Aurobindo Pharma and Dr. Reddy's Laboratories.

Does Neuland Laboratories have an API?

No public API is recorded for Neuland Laboratories.

What industry is Neuland Laboratories in?

Neuland Laboratories's product category is Pharmaceutical API Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAA, Small-Molecule API Process Development & Route Scouting. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StNeuland Laboratories Limited Just Missed Revenue By 9.3%: Here's What Analysts Think Will Happen NextNeuland Laboratories reported Q4 revenue of ₹4.5b, 9.3% below expectations, while statutory EPS of ₹284 was in line with estimates. Analysts downgraded 2027 revenue and EPS forecasts, but the consensus price target remained unchanged at ₹24,829.CNBCTV18Neuland Laboratories shares in focus after Q2 results see revenue drop and margin contraction - CNBC TV18Neuland Laboratories reported Q2 revenue of ₹449.65 crore, down 12.6% year-on-year, and net profit of ₹51.6 crore, down 46.7% from the prior year. Margins contracted to 24.1% from 30.2% a year earlier, and shares fell 0.9% ahead of the results.ScanXStocks to Watch Today, November 4, 2026: Camlin Fine Sciences, Neuland Laboratories, MEDANTA, Seamec and Savita Oil TechnologiesQ2FY27 earnings showed mixed results: Lloyds Metals and Savita Oil posted strong profits, while Camlin Fine Sciences faced a SEBI warning and Neuland Laboratories saw a 46.7% profit drop. Savita Oil's net profit surged 394% to ₹21,582.57 lakh, and Lloyds Metals' profit rose 84% to ₹1,045 crore.Investing.comEarnings call transcript: Neuland Laboratories posts softer Q2 2026 resultsNeuland Laboratories reported Q2 FY2027 revenue of INR 457.2 crores, down 11.4% year-over-year, and profit after tax of INR 51.1 crores, down 47.1%. The company attributed the decline to higher costs, a less favorable product mix, and uneven customer shipments, while citing strong RFP activity and a growing peptide pipeline.CNBCTV18Neuland Laboratories Q2: Profit falls 47%, revenue declines 12.5%; margins contract - CNBC TV18Neuland Laboratories reported a 46.7% year-on-year drop in net profit to ₹51.6 crore for the September quarter, with revenue falling 12.5% to ₹449.7 crore. EBITDA margin contracted to 21.7% from 30.2%, driven by heavy capital investments in research and peptide manufacturing. The company expects commercial CMS molecules to drive near-term growth.WhalesbookNeuland Labs Corrects 24% From September Peak Of ₹24,000Neuland Laboratories' shares fell 24% from a September 2026 peak of ₹24,000 as it shifts to a contract manufacturing model. The CMS division now accounts for 61% of revenue, with 19 products in commercial phase and plans for two to three new products. The stock trades at 42 times forward earnings, above its five-year average of 32.BusinessLineNeuland Laboratories: Betting on new growth avenuesNeuland Laboratories' stock corrected 24% from a September 2026 peak, trading at 42 times forward earnings. Its CMS division now accounts for 61% of FY26 revenue, and the company is expanding into peptides with a commercialized facility. Long-term investors may find current levels attractive given early growth phase.ET NOW5 midcap stocks show bullish technical signals even as Nifty Midcap 100 struggles; do you own any?Five midcap stocks—Honeywell Automation, PTC India, Neuland Laboratories, LMW, and Maharashtra Scooters—show bullish 50-day SMA crossovers despite the Nifty Midcap 100's decline. The index is trading below key moving averages, with these stocks having fallen 10-16% over the past month.NDTV ProfitHow A Rs 276 Stock Turned Into A Rs 20,000 Multibagger — Do You Own?Neuland Laboratories' share price rose from Rs 276 to Rs 20,000 over six years, delivering a 7,146% return. Total income grew from Rs 766.6 crore to Rs 2,053.1 crore, and profit after tax from Rs 15.9 crore to Rs 363.1 crore. Future growth depends on commercializing its peptide pipeline and expanding manufacturing capacity.CNBCTV18Neuland Laboratories gets record RFPs in three months as drugmakers diversify beyond China - CNBC TV18Neuland Laboratories received its highest number of Requests for Proposals in three months as global drugmakers seek to diversify supply chains beyond China. CEO Saharsh Davuluri said innovators are looking at India and Europe, and the company's US acquisition aligns with localizing complex molecules. India's top 10 CDMOs generate about $3.5 billion, far less than China's largest.